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Abstract
Background: Reports of the use of psyllium, largely in hypercholesterolemic men, have suggested
that it lowers serum cholesterol as a result of the binding of bile acids in the intestinal lumen.
Widespread advertisements have claimed an association between the use of soluble fibre from
psyllium seed husk and a reduced risk of coronary heart disease. Given the purported mechanism
of cholesterol-lowering by psyllium, we hypothesized that there would be a greater effect when
psyllium is taken with breakfast than when taken at bedtime. Secondarily, we expected to confirm
a cholesterol-lowering effect of psyllium in subjects with "average" cholesterol levels.
Methods: Sixteen men and 47 women ranging in age from 18 to 77 years [mean 53 +/- 13] with
LDL cholesterol levels that were normal or slightly elevated but acceptable for subjects at low risk
of coronary artery disease were recruited from general gastroenterology and low risk lipid clinics.
Following a one month dietary stabilization period, they received an average daily dose of 12.7 g of
psyllium hydrophilic mucilloid, in randomized order, for 8 weeks in the morning and 8 weeks in the
evening. Change from baseline was determined for serum total cholesterol, LDL, HDL and
triglycerides.
Results: Total cholesterol for the "AM first" group at baseline, 8 and 16 weeks was 5.76, 5.77 and
5.80 mmol/L and for the "PM first" group the corresponding values were 5.47, 5.61 and 5.57 mmol/
L. No effect on any lipid parameter was demonstrated for the group as a whole or in any sub-group
analysis.
Conclusion: The timing of psyllium administration had no effect on cholesterol-lowering and, in
fact, no cholesterol-lowering was observed. Conclusions regarding the effectiveness of psyllium for
the prevention of heart disease in the population at large may be premature.
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Background
A cholesterol lowering effect has been reported for a vari-
ety of soluble dietary fibres [1-5]. In February, 1998, the
U.S. Food and Drug Administration authorized the use,
on food labels and food labelling, of health claims on the
association between soluble fibre from psyllium seed
husk and a reduced risk of coronary heart disease [6].
Among the suggested mechanisms by which soluble fibre
lowers cholesterol is the binding of bile acids in the intes-
tinal lumen resulting in decreased absorption and
increased faecal excretion of them [7-15]. The ensuing bile
acid depletion increases hepatic demand for the de novo
synthesis of bile acids from cholesterol. This requirement
is met, in part, by increased hepatic LDL receptor activity,
which in turn reduces circulating LDL.
The accumulation and concentration of bile in the gall-
bladder is a continuous process. In rats which lack a gall-
bladder, the biliary excretion rate of bile salts is maximal
at night [16] and bile is stored in the gallbladder during
an overnight fast. To the extent that the cholesterol-lower-
ing effect of psyllium requires an interaction with bile, the
magnitude of its cholesterol-lowering effect should vary
with the quantity of bile in contact with a given amount
of psyllium. The gallbladder empties with a meal and the
total quantity of bile salt presented to the small bowel
should be highest when this emptying occurs at breakfast,
following a fast and the associated overnight accumula-
tion of secreted bile. Conversely, psyllium presented to
the gut following a short fast and without the full stimulus
to gallbladder emptying of an associated meal should
result in an encounter with a smaller amount of bile. We
accordingly set out to test the hypothesis that administer-
ing psyllium with breakfast would have a significantly
greater cholesterol-lowering effect than would taking a
similar dose at bedtime. Since the predominance of the
literature with regard to the cholesterol-lowering effect of
psyllium is in individuals with hypercholesterolemia, a
secondary goal of our study was to confirm the choles-
terol-lowering effect of psyllium in subjects with "aver-
age" cholesterol levels.
Methods
Patients identified in gastroenterology practices as requir-
ing long-term treatment with psyllium, typically for
chronic constipation or the irritable bowel syndrome,
were invited to participate in the study. In addition, indi-
viduals who had received dietary counselling in a lipid
clinic regarding cholesterol-lowering and who subse-
quently had cholesterol levels deemed not to require fur-
ther intervention because they met targets set out in
clinical practice guidelines were invited by clinic staff to
participate. Subjects were deemed ineligible if they were
under age 18 years, were under active treatment for hyper-
lipidemia, had total cholesterol greater than 7.00 mmol/
L, required alterations in dosage of medications which
might have an effect on lipid levels, had had a gastrec-
tomy, had any disease which is associated with hyperlipi-
demia, were receiving a bile acid binding resin, or if they
did not eat breakfast regularly.
The study was approved by the Conjoint Health Research
Ethics Board of the University of Calgary, Faculty of Med-
icine. Subjects were given a description of the study indi-
cating our interest in comparing the relative efficacy of hs
versus am dosing with psyllium without indicating the
specific hypothesis, and were asked to sign a consent
form.
Gastroenterology patients were given a high fibre diet
sheet as part of their therapeutic regimen and were asked
to take this on a continuing basis, beginning one month
prior to the initiation of the study. The diet sheet empha-
sized dietary sources containing predominantly insoluble
fibre. Lipid clinic patients had all received in-depth coun-
selling regarding dietary measures for hypercholestero-
lemia, including a high fibre regimen, and had
implemented their dietary changes at least one month
before beginning the study. An unsweetened psyllium
preparation, "Novo-Mucilax" [NovoPharm], providing
three grams of hydrophilic mucilloid per 6.2 gram pow-
der, and a scoop known to provide at least ten grams of
psyllium were provided. Containers were numbered and
weighed at the conclusion of each test interval. Subjects
were randomized to initially take a scoop full of psyllium
either with breakfast or at bedtime. Using a crossover
design, psyllium was taken in the morning or evening for
eight weeks and at the alternate time for the subsequent
eight weeks.
Determinations of serum total cholesterol, LDL, HDL and
triglycerides were made before beginning psyllium, at
eight weeks and at sixteen weeks after commencing its use.
A trained dietician obtained a dietary history and patients
were weighed at the beginning and at the conclusion of
the study. All lipid determinations were undertaken fol-
lowing a 14 hour fast and analyses were done in a central
laboratory.
After initial data inspection based on boxplots and sum-
mary measures, cholesterol values at 8 and 16 weeks were
examined using analysis of variance, taking into account
treatment, period, and between and within subject effects
in accordance with the cross-over design. The pattern of
change from baseline to 16 weeks was evaluated using
paired t-tests.
Results
Of 86 subjects beginning the study, 33 of those referred
from the gastroenterology clinics and 30 of those referredNutrition Journal 2004, 3:17 http://www.nutritionj.com/content/3/1/17
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from the lipid clinic completed it. Of those withdrawing,
eight did so because they could not tolerate the psyllium
or it was felt to interfere with prescribed medication, 2
had elevated lipids, 4 did not complete all the required
blood work, 5 were unable to comply with the protocol
because of work or lifestyle changes and 4 developed
intercurrent diseases which precluded completing the
protocol.
The age range of subjects was 18 to 77 years, mean 53 +/-
13 years, including 16 men and 47 women. The mean
dose of psyllium taken was 12.7 +/ - 2.3 g for morning
dosing and 12.7 +/- 2.2 g when taken in the evenings.
Values for total, LDL, HDL cholesterol and triglycerides at
baseline, eight and sixteen weeks for various subgroup-
ings are tabulated in tables 1, 2, 3 and 4, respectively. Data
for changes from baseline for total, LDL and HDL choles-
terol and triglycerides are listed in table 5. Changes from
baseline were not significant for any parameter. Further-
more, the confidence intervals given in Table 5 show that
this data essentially excludes a clinically significant psyl-
lium effect.
Table 1: Total Cholesterol in mmol/L [SD]
[n] Baseline 8 wks 16 wks
AM first 5.76 [0.94] 5.77 [1.01] 5.80 [0.95]
PM first 5.47 [0.98] 5.61 [1.10] 5.57 [1.06]
Females [47] 5.72 [0.96] 5.79 [1.07] 5.74 [0.99]
Males [16] 5.29 [0.94] 5.39 [0.96] 5.48 [1.04]
GI subjects [33] 5.00 [0.83] 5.06 [0.91] 5.07 [0.84]
Lipid clinic Subjects [30] 6.28 [0.59] 6.39 [0.69] 6.35 [0.70]
All subjects [63] 5.61 [0.96] 5.69 [1.05] 5.68 [1.00]
"AM first" are subjects taking psyllium in the morning for the first 8 weeks and in the evening for the second 8 weeks. Vice versa for "PM first".
Table 2: LDL CHOLESTEROL in mmol/L [SD]
Baseline 8 wks 16 wks
AM first 3.55 [1.01] 3.51 [1.04] 3.52 [0.94]
PM first 3.39 [0.90] 3.43 [1.03] 3.45 [0.92]
Females 3.55 [0.92] 3.54 [1.04] 3.52 [0.92]
Males 3.22 [1.03] 3.24 [0.99] 3.39 [0.97]
GI subjects 2.89 [0.81] 2.85 [0.85] 2.91 [0.72]
Lipid clinic subjects 4.09 [0.66] 4.15 [0.72] 4.11 [0.69]
All subjects 3.47 [0.95] 3.47 [1.03] 3.48 [0.92]
Table 3: HDL CHOLESTEROL in mmol/L [SD]
Baseline 8 wks 16 wks
AM first 1.38 [0.29] 1.42 [0.37] 1.42 [0.33]
PM first 1.38 [0.40] 1.39 [0.36] 1.36 [0.33]
Females 1.41 [0.30] 1.44 [0.30] 1.42 [0.29]
Males 1.28 [0.45] 1.29 [0.50] 1.30 [0.43]
GI subjects 1.36 [0.39] 1.41 [0.43] 1.37 [0.38]
Lipid clinic subjects 1.40 [0.30] 1.40 [0.28] 1.41 [0.27]
All subjects 1.38 [0.35] 1.41 [0.36] 1.39 [0.33]Nutrition Journal 2004, 3:17 http://www.nutritionj.com/content/3/1/17
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The mean caloric intake or the intakes of fat or fibre did
not change significantly during the study [table 6]. There
was a small but significant increase in the weights of sub-
jects, which was felt to reflect the high proportion of sub-
jects beginning the study in the fall and the associated
reduction of physical activity during the subsequent win-
ter months. There was no apparent relationship between
change in cholesterol and change in weight [correlation =
.1, p = .15].
Discussion
We failed to prove our hypothesis that administration of
psyllium in the morning would have a greater cholesterol-
lowering effect than it would in the evening. Not only was
there no observable difference in lipid levels between the
crossover periods but the daily ingestion of a greater daily
dose than the 10.2 g of psyllium for which the FDA allows
health claims to be made [6] had no effect on lipid levels
in our study group. No change in any lipid parameter,
including total and LDL cholesterol was observed. No
difference was found when subgroup analysis was under-
taken for the sex of the patients, the time of day they took
their psyllium, or whether they were recruited from the
gastroenterology clinic or the lipid clinic.
We used a crossover design since this was the most appro-
priate one for the primary question being addressed;
accordingly, our study did not include a control group.
However, the nature of the study should not have pro-
vided any motivation for study subjects to adopt any new
Table 4: TRIGLYCERIDES in mmol/L [SD]
Baseline 8 wks 16 wks
AM first 1.81 [0.70] 1.84 [0.86] 1.86 [0.91]
PM first 1.53 [0.52] 1.69 [0.70] 1.65 [0.61]
Females 1.66 [0.61] 1.72 [0.70] 1.76 [0.71
Males 1.70 [0.68] 1.89 [0.99] 1.72 [0.94]
GI subjects 1.63 [0.54] 1.71 [0.82] 1.70 [0.72]
Lipid clinic subjects 1.71 [0.71] 1.82 [0.74] 1.80 [0.83]
All subjects 1.67 [0.35] 1.76 [0.78] 1.75 [0.77]
Table 5: Mean changes from baseline at 8 and 16 weeks [mmol/L] and 95% confidence intervals [all patients, n = 63]
8 wks 16 wks
TOTAL 0.080 p = 0.26 0.068 p = 0.28
CHOLESTEROL [-0.061,0.22] [-0.056,0.19]
LDL 0.002 p = 0.98 0.018 p = 0.75
CHOLESTEROL [-0.13,0.14] [-0.098,0.13]
HDL 0.028 p = 0.28 0.012 p = 0.61
CHOLESTEROL [-0.023,0.08] [-0.035,0.059]
TRIGLYCERIDES 0.094 p = 0.22 0.082 p = 0.22
[-0.059,0.25] [-0.050,0.21]
Table 6: Weight and Dietary Intake [SD] at Baseline and at 16 Weeks
Baseline 16 wks
WEIGHT [Kg] 74.6 [16.5] 75.4 [16.9] p = 0.0039
ENERGY [kcal] 1649 [409] 1689 [419] p = 0.29
FAT [g] 49.1 [20.3] 49.8 [20.2] p = 0.66
FIBER [g] 19.7 [7.96] 19.7 [7.28] p = 0.99Nutrition Journal 2004, 3:17 http://www.nutritionj.com/content/3/1/17
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lifestyle or dietary changes beyond those implemented
well before the introduction of psyllium. Observational
data has been shown to provide valid information, which
is consistent with that observed in randomized, control-
led trials [17,18]. The nature of the intervention was in
keeping with those undertaken in day-to-day clinical prac-
tice and the protocol used should, therefore, have high
"clinical relevance".
Failure of lipid-lowering by psyllium has also been dem-
onstrated in twenty hypercholesterolemic children [19],
in twenty-four hyperlipidemic adults [20] and in a large
observational study of elderly patients taking psyllium
[21]. A report of lipid-lowering therapies in hypercholes-
terolemic veterans showed only a 2% reduction in LDL
cholesterol and a small increase in LDL/HDL ratio in
patients taking psyllium, but does not provide a measure
of statistical significance [22]. One study revealed no dif-
ference in total cholesterol-lowering compared to pla-
cebo, but a reduction of LDL cholesterol resulted from
psyllium treatment [23]. Another demonstrated no differ-
ence in total cholesterol-lowering compared to placebo, a
reduction of LDL in 11 "responders" and no change in 9
"nonresponders" [24]. A reduction of HDL cholesterol
has been noted in some studies [25-27] and was associ-
ated with changes in LDL/HDL ratios similar to placebo
treatment [25,26].
Published studies include few normocholesterolemic sub-
jects. Cholesterol reduction was observed in 7 normal
men [28] and in 5 of 9 subjects [29], in both studies after
3 weeks of treatment. A reduction of cholesterol levels was
also observed in 12 elderly patients given psyllium for 4
months [30], while 5 normocholesterolemic subjects in
another study showed no reduction after 2 to 7 months of
treatment [31].
A meta-analysis of 17 studies of patients with hypercho-
lesterolemia has suggested a small but significant choles-
terol-lowering effect of psyllium [2]. All of these
investigations were associated in one way or another with
the product manufacturer. Additional studies have also
indicated some cholesterol-lowering by psyllium in
hypercholesterolemic individuals [32-37] or in diabetics
[38-40]; however, much of this work is uncontrolled and
some protocols have specifically excluded premenopausal
women [33,38]. The association of cholesterol-lowering
effects with psyllium may be weakened in some studies by
the use of a supplement containing additional forms of
soluble fibre [42] or by apparent differences in intake of
calories [43-46], soluble fibre [25] or cholesterol [47] in
control and treatment groups or periods. Several reports
include only small numbers of patients and/or are of
short duration. There is a strong predominance of male
subjects in these publications and some protocols incor-
porate additional treatment interventions [20,48].
Several factors may contribute to the difference between
our observations and those of others. A meta-analysis has
demonstrated that the initial level of cholesterol was
highly predictive of the subsequent reduction of choles-
terol by oat bran [49]. A greater effect of psyllium in men
compared to women has been suggested [23,46] and a
diet high in soluble fibre produced less cholesterol-lower-
ing in post menopausal women than in men [10]. Soluble
fibre has a lesser effect on lipid metabolism in female than
in male guinea pigs [50] and there is a sex-based differ-
ence in mechanism of action in this animal [51]. Oat bran
fails to lower cholesterol in young women, in contrast to
men and older women [52]. The dominance of women in
our study, the "normal", or only slightly abnormal choles-
terol states of our subjects and the relatively young ages of
some of them may, accordingly, account for some of the
variance of our observations with some of those previ-
ously reported.
The small increase in the weight of subjects is believed to
be have resulted from reduced physical activity. In a meta-
analysis of the effect of weight reduction on lipids, pre-
dominantly through dietary change, a reduction in total
cholesterol of 0.05 mmol/L and of 0.02 mmol/L in LDL
cholesterol per kilogram of weight lost was identified
[53]. Dietary intakes were stable throughout our study
and the average weight gain of less than one kilogram is
very unlikely to have raised cholesterol levels to a degree
sufficient to offset a significant cholesterol lowering effect
of psyllium.
A small cholesterol-lowering effect of psyllium appears to
occur in hypercholesterolemic individuals, at least in men
and possibly postmenopausal women. The notion of a
benefit accruing to the general population requires addi-
tional study. The promotion of foods containing psyllium
as reducing the risk of heart disease for the population at
large [6] may be premature. Additional study is required
and this should be undertaken in a manner that is free
from concern regarding the possibility of publication bias
which Brown L, Rosner B, Willett WW and Sacks FM have
raised [2].
Conclusion
The timing of psyllium administration had no effect on
cholesterol-lowering and, in fact, no cholesterol-lowering
was observed. Conclusions regarding the effectiveness of
psyllium for the prevention of heart disease in the popu-
lation at large may be premature.
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